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Abstract 
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the 
development of multiple tumors in the central nervous system, most notably schwannomas and 
meningiomas. Mutational inactivation of the NF2 gene encoding the protein Merlin is found in 
most sporadic and inherited schwannomas, but the molecular mechanisms underlying neoplastic 
changes in schwannoma cells remain unclear. We report here that Nf2-deficient cells display 
elevated expression levels of key enzymes involved in lipogenesis and that this upregulation is 
caused by increased activity of Torc1. Inhibition or knockdown of fatty acid synthase (FASN), 
the enzyme that catalyzes the formation of palmitic acid from malonyl-CoA, drove NF2-
deficient cells into apoptosis. Treatment of NF2-mutant cells with agents that inhibit the 
production of malonyl-CoA reduced their sensitivity to FASN inhibitors. Collectively, these 
results suggest that the altered lipid metabolism found in NF2-mutant cells renders them 
sensitive to elevated levels of malonyl-CoA, as occurs following blockade of fatty acid synthase, 




Neurofibromatosis type 2 (NF2) is an autosomal dominant cancer predisposition syndrome that 
occurs due to inactivating mutations in the NF2 gene. NF2 is characterized by formation of 
multiple low grade tumors along the peripheral nerves and in the central nervous system (1), and 
associated with disease manifestations that include benign schwannomas (including bilateral 
vestibular schwannomas, the hallmark of the disease), meningiomas, and ependymomas. Despite 
the benign nature of these lesions, NF2 is often fatal due to development of inoperable 
intracranial tumors. In addition, somatic mutations in the NF2 gene also contribute to malignant 
mesotheliomas and other tumors (2). To date there is no effective pharmacotherapy for NF2 and 
the morbidity and mortality of this inherited disorder remains high. 
 
The NF2 gene product, merlin, is a member of the ezrin-moesin-radixin protein family and 
functions to regulate cell adhesion via receptor tyrosine kinases and integrins (3-7), proliferative 
and survival signaling via enzymes such as Rac, PAK, AKT, FAK, and MTOR (8-11), and to 
suppress tumorigenesis via inhibition of the E3 ubiquitin ligase CRL4/DCAF1 complex (12). In 
addition, Merlin signaling may also impact the MST/YAP contact inhibition signaling pathway 
(13). Loss of NF2 gene leads to inability of cells to form stable cell:cell junctions (14), and NF2-
deficient cells do not show contact growth inhibition (4,14). Conversely, Merlin overexpression 
blocks proliferation (15). 
 
Currently, three targeted therapeutic approaches are being investigated for potential use in NF2: 
angiogenesis inhibitors such as bevacizumab (16,17), EGFR inhibitors such as erlotinib and 
lapatinib (18), and MTOR inhibitors such as sirolimus and everolimus (19). While the use of 
such targeted agents has shown promise in early trials, the redundancy of proliferative, survival, 
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and motility signaling cascades in Merlin-null cells suggests a need to identify additional 
therapeutic concepts and targets in this disorder.  
 
Recently, there has been revived interest in targeting metabolic enzymes in various malignancies. 
Most of these efforts have attempted to exploit unique aspects of sugar metabolism in cancer, the 
so-called Warburg effect. However, cancer cells also require large amounts of lipid for 
membrane biosynthesis, energy, and signal transduction and such lipids are supplied by de novo 
fatty acid synthesis (20). Accordingly, enzymes involved in fatty acid metabolism, such as fatty 
acid synthase (FASN), are commonly upregulated in cancer cells, and inhibiting FASN or other 
enzymes involved in lipogenesis can induce apoptosis in such cells (21,22). These data show that 
enzymes involved in lipid metabolism are potential therapeutic targets against cancers.  
 
In this report, we used Nf2-deficient vs. WT cells to screen for metabolic changes caused by Nf2 
gene loss. We found that Nf2-deficient fibroblasts and Schwann cells display a variety of 
metabolic derangements involving lipid metabolism, in particular, a significant elevation of fatty 
acid levels. Further studies showed that Nf2-deficient cells are selectively sensitive to inhibitors 
of fatty acid synthase (FASN). We report that siRNA or small molecule inhibitors of FASN are 
toxic to Nf2-deficient cells, and that this toxicity appears to be related to a build up of pro-
apoptotic metabolic intermediates, in particular malonyl-CoA. Our findings define a new aspect 
of NF2 pathobiology that could be used to identify therapeutic agents in this syndrome.  
Methods 
Plasmids, antibodies, and reagents. pBabe-NF2 was obtained from Addgene. Anti-Fasn 
siRNA (M-040091-01-0005), anti-Acaca siRNA (M-063938-01-0005), anti-Mtor (M-065427-
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00-0005), anti-Rptor (M-058754-01-0005), anti-Rictor (M-064598-01-0005) and non-silencing 
(D-001206-13-05) siRNA were purchased from Dharmacon. Individual siRNAs against Mtor 
(SASI_Mm01-00164496 and -00164492), Rictor (-00137732 and -00137730), Rptor (-00055298 
and -00334580), Fasn (-00177858 and -00177854), Acaca (-0011590 and -00115905), and 
Mlycd (-00028572 and -00028576) were purchased from Sigma-Aldrich. Anti-Merlin antibodies 
were purchased from Abcam (#ab88957). Lipid synthesis and metabolism antibody kit (includes 
anti-Fasn, -phospho ACC, -ACC, -Lipin1, -ACLY, -phospho ACLY, -ACSL1, and -ACECS1 
antibodies), and anti-Casp3 antibodies were purchased from Cell Signaling Technology. Anti-
SREBP1 antibodies were purchased from Santa Cruz Biotechnology. Anti-GAPDH antibodies 
were purchased from EMD-Millipore. 
 
Cerulenin, C75, luteolin, 5-(tetradecyloxy)-2-furoic acid (TOFA) and 5-iodotubercidin were 
purchased from Enzo Life Sciences. GSK2194069, dimethylsulfoxyde (DMSO), staurosporin, 
sodium palmitate, 70% perchloric acid, ammonium formate, acetonitrile, acetyl-coenzyme A 
lithium salt, malonyl coenzyme A lithium salt, propionyl-coenzyme A lithium salt, and poly-L-
lysine were purchased from Sigma-Aldrich. 
 
Cell culture. DMEM, DMEM/F12, PBS, N2 supplement, 0.05% trypsin, and Alamar Blue were 
purchased from Life Technologies. Fetal bovine serum was purchased from Atlanta Biologicals, 
heregulin-1 from R&D Systems, forskolin and laminin from EMD Millipore, and the WST-1 
assay kit from Clontech. 
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Nf2f/f mouse embryo fibroblasts (MEFs) carrying flox site in exon 2 of Nf2 gene (23), FC912 
(Nf2f/f) mouse Schwann cells, FH912 (Nf2-deficient) mouse Schwann cells, and SC4-9 (Nf2-
deficient) mouse schwannoma cells were a generous gift of Dr. Marco Giovannini (House Ear 
Institute, CA), obtained in 2012. RT4 rat schwannoma cells were obtained from ATCC in 2012. 
All cell lines except FH912 and FC912 were grown in DMEM GlutaMAX with high glucose, 1 
mM sodium pyruvate, 0.1 mM non-essential amino acids and 10% FBS at 37°С, 5% СО2. 
FH912 and FC912 cells were grown in DMEM:F12 with 2 mM forskolin, 10 ng/ml heregulin, 
and N2 supplement on laminin-poly-L-lysine coated plates. MEF Nf2f/f cells were immortalized 
with pMSE-SV40LT plasmid. Deletion of the Nf2 gene from MEF Nf2f/f cells was achieved by 
transfecting these cells with a pMSCV-Cre-GFP plasmid and sorting for GFP-positive cells. Cell 
line authentication was confirmed by two methods. First, Nf2 deletion was confirmed by PCR 
genotyping and by immunoblotting (data not shown). Second, the species of origin was 
confirmed by short tandem repeat profiling. For the reexpression of merlin in Nf2-deficient 
schwannoma cells SC4-9 cells were transiently transfected with pBabe-NF2-puro plasmid. 
Control cells were transfected with pBabe-puro plasmid. Merlin expression level was detected by 
immunoblotting (Fig. S1). Untreated plates for growth control were grown in parallel with 
experimental plates. 
 
Cells were grown in 10-cm culture plates for no longer than 30 passages and allowed to grow for 
3-4 passages after thawing before the actual experiments started. Each cell line was tested for 
mycoplasma upon thawing every new vial of cells (at the time of 3d passage after thawing) using 
mycoplasma growth indicator cultures of Vero cells, detected by fluorescence microscopy using 
the DNA-specific fluorochrome Hoeschst 33258. Proliferation studies were done in 96-well 
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plates with initial cell density 104 cells/well. Immunoblotting was done in 6-well plates with 
initial density 2.5 х 105 cells/well. For lipogenesis-related protein immunoblotting cells were 
grown in serum-free conditions. For mitochondrial respiration assay cells were grown in 96-well 
plates provided with the analyzer at initial density 4x103 cells/well. For RNA extraction cells 
were grown in 6 cm culture plates until confluent in serum-free conditions. For UPLC-MS/MS 
and metabolomic studies cells were grown in 30 cm culture plates until confluent. 
 
Primary schwannoma cell cultures: After informed consent, human primary schwannoma tissue 
samples were collected during operations at Derriford Hospital (Plymouth, UK) or Southmead 
Hospital (Bristol, UK) under local R&D approval Plymouth Hospitals NHS Trust: R&D No: 
14/P/056 and North Bristol NHS Trust: R&D No: 3458. Cells were isolated by digestion using a 
mixture of collagenase, dispase and mechanical digestion by pipetting. Once digested cells were 
cultured in growth factor medium (GFM): DMEM, 10% FBS, 100U/ml pen/strep; 0.5µM 
Forskolin; 2.5µg/ml Amphotericin; 2.5 µg/ml Insulin; 10nM β1 heregulin, maintained in a 
humidified atmosphere of 10% CO2 at 37ºC on plates coated with both poly-L lysine and 
laminin. Human schwannoma primary cells (passages 1-4) and used in this study are Merlin-
negative. All Schwann cell cultures are S100 positive. 
 
Primary meningioma and Human meningeal cell (HMC, Catalog #1400, ScienCell Research 
Laboratories) cultures: All the meningioma tumour samples used were collected under the MOT 
project involving both Derriford and Southmead Hospitals. The project was granted full ethics 
approval by the South West research ethics committee (REC number 14/SW/0119). All tumours 
used in this project were classified as WHO grade 1. Meningioma cells were isolated using a 
mixture of collagenase, dispase and mechanical digestion by pipetting. Once 
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digested Meningioma cells were grown in DMEM containing glucose (4.5 g/l), 10% FBS, 100 
U/ml penicillin/streptomycin and 1% glutamine. Human meningeal cells (HMC, Sciencell, CA, 
USA) were grown in the recommended HMC medium (Sciencell) at 37 °C and 5% CO2. Human 
meningioma grade I primary cells (passages 1-4) used in this study are Merlin-negative. 
All primary cells were grown in Mycoplasma ExS (PromoCell GmbH, Heidelberg, Germany) 
treated incubators. No additional mycoplasma testing was performed. 
 
Proliferation and viability assays. Proliferation and viability were evaluated by Alamar Blue 
reagent according to the manufacturer’s protocol. For the human schwannoma and meningioma 
samples immunofluorescence proliferation and viability assays were performed: cells were 
cultured for 72 h in GFM with or without GSK2194069 (0.1, 1 and 10 µM). Pre-treated cells 
were fixed using 4% paraformaldehyde (PFA) and permeablised using 0.2% Triton X-100 before 
being blocked using 10% normal goat serum. Cells were then incubated with primary antibodies 
overnight at 4° C at a concentration of 1:100 in 1%BSA Phosphate-buffered saline (PBS). Anti-
Ki67 (Dako) was used as a marker or proliferating cells and anti-cleaved caspase-3 (Cell 
Signalling Technologies) was used as a marker or cells undergoing apoptosis. AlexaFluorTM 
secondary antibodies goat-anti mouse 594 and goat-anti rabbit 488 were used and DAPI applied 
as a nuclear stain. 
Confocal Microscopy: Multitrack imaging was performed using a Zeiss Confocal LSM510. 
Proliferation and survival assays which were carried out using a 20x air objective. The 
appropriate Zeiss image manipulation software (ZEN) was used for editing. 
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Transfections were done by electroporation using Neon transfection system (Life Technologies, 
Grand Island, NY) according to manufacturer’s protocol. Transfections were done in 100 L 
tips. For DNA transfections final concentration of 5 g per reaction was used. For RNA 
transfections final concentration of 100 nM was used. 
 
Immunoblotting. Cells were lysed with RIPA (1% Triton-X100; 10% glycerol; 50 mM HEPES, 
pH 7.4; 150 mM NaCl; 1.5 mM MgCl2, 1 mM EGTA,
 1 mM EDTA, 0.1% SDS, 10 mM 
phenylmethylsulphonyl-fluoride; aprotinin 10 µg/mL, leupeptin 10µg/mL, pepstatin 10 µg/mL, 
10 mM sodium fluoride) for 15 min. on ice. Proteins of interest were detected by regular 
immunoblotting using a Lipid synthesis and metabolism antibody kit, anti-cleaved Casp3 rabbit 
monoclonal antibody, and mouse anti-merlin, anti-Actin, anti-Srebp1 and anti-Gapdh 
antibodies. Goat anti-rabbit HRP-conjugated and anti-mouse AP-conjugated immunoglobulins 
were used with Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA) and 
ImmunStar AP substrate (Bio-Rad, Hercules, CA). Bands were visualized on FluorChem™ E 
System (ProteinSimple, Santa Clara, CA) and analyzed using ImageJ software. Band intensities 
were normalized to Gapdh or -Actin band intensities. 
 
qPCR. Cells were grown in serum-free media in 6-cm plates until confluent, and total RNA was 
extracted using RNeasy Minikit (Qiagen, Valencia, CA). Quantitative RT-PCR reactions were 
performed using TaqMan probes and primers designed by the manufacturer, using an ABI 
PRISM 7700 detection system (Applied Biosystems, Foster City, CA). Results were analyzed 
using relative standard curve method. For Acacb comparative Ct method was used. The average 
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of Hprt1, Tbp and Actinb expression was used for normalization. See Supplemental data for the 
complete list of primers. 
 
Acyl-CoA quantification. 4 types of samples were analyzed: and MEF Nf2-/-, treated with 
DMSO, MEF Nf2-/-, treated with cerulenin, MEF Nf2f/f, treated with DMSO, and MEF Nf2f/f, 
treated with cerulenin. ~1 g of cell pellet per sample type was used for analysis. Propionyl-CoA 
was used as a recovery standard. After the solid phase extraction acidified and neutralized 
samples were put to the Waters Acquity H-class ultra-high performance liquid chromatography 
(UPLC, Milford, MA) with the isocratic mobile phase: 50 mM ammonium formate:acetonitrile 
(30:70, v/v). The eluates were directly introduced into the coupled Thermo triple quadrupole 
mass spectrometer (TSQ Quantum Access, Waltham, MA) for quantitative analysis. See 
Supplemental data for the complete procedure description. 
 
Mitochondrial respiration measurement. The study was performed in a 96-well format on a 
Seahorse XF analyzer using Seahorse Mito Stress Kit (Seahorse Bioscience, N. Billerica, MA, 
USA) according to the manufacturer’s protocol. Initial cell density was 4x103 cells/well. Upon 
assay completion cells were lysed and used for protein concentration assay (Bradford). All data 
was normalized to protein concentrations. 
 
Animal studies. All animal procedures were performed in accordance with IACUC guides and 
regulations. Mouse schwannoma xenografts were performed on female nu/nu mice, n=5. 3 x 106 
SC4-9 cells in matrigel per mouse were injected subcutaneously. A 100x stock solution of 
cerulenin was prepared in DMSO:ethanol (1:4) and stored at -20oC. A working solution in corn 
 11 
oil was prepared daily and given by oral gavage at a dose of 30 or 2 mg/kg/day (cerulenin) and 3 
mg/kg/day (GSK2194069) starting day 3 after injection. Mice were sacrificed by cervical 
dislocation after 4 weeks of treatment.  
 
Metabolic studies. 6 groups of samples were analyzed: non-treated Nf2-deficient mouse 
Schwann cells FH912 and wild type mouse Schwann cells FC912; non-treated Nf2-/- and Nf2f/f 
MEFs; and Nf2-/- and Nf2f/f MEFs treated with 5 M cerulenin for 24 hours. 5 samples per 
sample type were prepared according to Metabolon sample preparation guidelines (Metabolon 
Inc., Durham, NC).  
 
Half inhibitory concentration (IC50). Drugs were added to the cells 4 hours after plating and 
incubated for 48 hours. For Acaca knockdown C75 was added next day after transfection and 
incubated for 48 hours. IC50 was calculated by the following formula: IC50=a+b*arctg(1-1/2c) 
after minimization of quadratic distance between experimental data and a fit curve y=с*(1-tg((x-
a)/b)), where x is the drug concentration, by modifying coefficients а, b and с. 
 
Statistical analysis. All IC50 studies were done in quadruplicates and repeated 4 times. Fasn and 
Acaca knockdown and ACC1 chemical activation and inhibition experiments were done in 
quadruplicates and repeated 3 times. Mlycd knockdown was done in quadruplicates and repeated 
4 times. Lipogenesis immunoblotting and qPCR studies were repeated 4 times. MTOR signaling 
and MTOR inactivation experiments were repeated 2 times. UPLC-MS/MS studies were 
repeated 3 times. Mean values and confidence interval 95% were used to build graphs. Statistical 
significance p was determined by two-tailed Student’s t-test with Welch’s correction for 
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increased Casp3 cleavage studies, UPLC-MS/MS, and for in vivo studies; and by Holm-Sidak 
method with =5% for lipogenesis immunoblotting and qPCR studies. For the schwannoma 
xenograft FASN expression p-value was calculated by Mann-Whitney test. For human 
schwannoma samples ANOVA was used. Experiments were performed in at least triplicates 
using at least three independent batches of cells from different individuals. In a figure, mean ± 
s.e.m. is given. 
 
Results 
Metabolic profiling of Nf2-deficient cells. We performed metabolic profiling of Nf2-deficient 
MEFs and Schwann cells (FH912) in comparison with WT MEFs (Nf2f/f) and Schwann cells 
(FC912) to see if metabolic pathways were altered by loss of the Nf2 gene. Metabolite profiling 
showed a broad spectrum of changes in Nf2-deficient cells. Specifically, we observed elevated 
levels of tricarbonic acid (TCA) cycle metabolites in Nf2-/- MEFs (Table 1) and increased levels 
of long chain and branched fatty acids in both FH912 Schwann cells and Nf2-/- MEFs (Table 2), 
consistent with increased energy demand in these cells (24-26). An increase in vitamins and 
cofactors levels was also observed (Table S1), especially, nicotinate metabolites involved in 
electron chain transport (NAD+, NADH, and NADP) and pantothenate metabolites involved in 
coenzyme A turnover, consistent with an increased energy production in Nf2-deficient cell lines 
(27). In addition, the level of metabolites associated with glycolysis was decreased in both 
FH912 Schwann cells and Nf2-/- MEFs (Table 1), as well as a drop in amino acids, including 
particularly glutamine metabolites (Table S2), suggesting upregulated glutaminolysis supporting 
the more active TCA cycle. The most profound metabolic alteration, however, was the marked 
elevation of fatty acid levels in both FH912 cells and Nf2-/- MEFs (Table 2). 
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Loss of the Nf2 gene renders cells vulnerable to FASN inhibitors. Since metabolic profiling 
indicated elevated fatty acid metabolism in Nf2-/- cells, we asked if these cells were sensitive to 
small molecule inhibitors of FASN. We found that the FASN inhibitor cerulenin (28) showed 
consistent selective toxicity against Nf2-deficient MEFs with IC50 ratio of 0.436±0.09, p=4E-10 
(Fig. 1A). The schwannoma cell lines SC4-9 and RT4 were also sensitive to similar levels of this 
compound. Re-expression of Merlin in SC4-9 cells rendered these cells insensitive to cerulenin 
(almost two-fold difference in IC50 values, p < 0.0001) (Fig. 1B), indicating that the sensitivity to 
cerulenin is related to Merlin expression (Merlin expression level is shown on fig. S1A). To 
ensure that the observed effects were related to FASN inhibition, we asked if Nf2-/- MEFs were 
more sensitive than Nf2f/f MEFs to knockdown of Fasn. Nf2-/- and Nf2f/f MEFs were transfected 
with pooled anti-Fasn siRNA or control non-silencing siRNA. Within 24 hours, rounded 
apoptotic cells were observed in Nf2-/- cells transfected with anti-Fasn siRNA, but not in the 
control cells or in transfected Nf2f/f MEFs. We observed a significant increase of Casp3 cleavage 
in anti-Fasn siRNA-transfected (4.14-fold, p=0.0001) Nf2-/- MEFs, but not in similarly treated 
Nf2f/f MEFs (Fig. 1C and S1B). Low dose cerulenin treatment also decreased levels of FASN at 
some degree, and the same trend of cleaved Casp3 increase was observed in Nf2-/- MEFs (2.01-
fold, p=0.022). The same pattern was observed when individual oligos against Fasn and 
GSK2194069 inhibitor were used (fig. S1C). We also tested the sensitivity of Nf2f/f and Nf2-/- 
MEFs to three additional small molecule FASN inhibitors: GSK2194069 (29), C75 (25), and 
Luteolin (25). In each case, loss of Nf2 was associated with higher sensitivity to the FASN 
inhibitors (Fig. 1D-1F).  
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We next performed xenograft studies on female nu/nu mice using SC4-9 cells. Xenografts were 
placed in the flanks and the mice were treated with cerulenin (30 mg/kg/day), GSK2194069 (3 
mg/kg/day), or vehicle for 28 days. As shown in Figure 1G, treatment with GSK2194069 caused 
a nearly two-fold reduction in tumor growth (p=0.0049), and cerulenin treatment caused a three-
fold reduction (p=0.00039), consistent with the notion that inhibiting FASN represents a 
potentially effective strategy for NF2. At the dose given mice tolerated treatment well and did 
not experience weight loss or skin dryness. Remarkably, much lower doses of cerulenin (2 
mg/kg/day) also effectively slowed down the tumour growth (Figure S1D). As has been reported 
previously (30) treatment with cerulenin was associated with a significant FASN expression 
decrease detected by immunoblotting of the tumor samples (Fig. S1D). 
 
Human primary schwannoma and meningioma cells exhibit similar sensitivity to FASN 
inhibition. To test whether normal FASN functioning was crucial for human schwannomas and 
meningiomas as well as mouse tumours we tested series of GSK2194069 concentrations on 
primary human schwannoma and meningioma cells obtained from the tumour samples in 
comparison to normal human Schwann and meningeal cells. Primary human schwannoma cells 
showed similar sensitivity compared to Nf2-/- MEFs and mouse schwannoma SC4-9 (IC50 0.68 ± 
0.26 M vs 0.19 ± 0.45 M and 0.3 ± 0.09 M, respectively) (Fig. 2А). Remarkably, normal 
Schwann cells turned to be virtually insensitive to GSK2194069 (Fig. 2А). Primary human 
meningioma cells also displayed similar sensitivity to the compounds, while normal human 
meningeal cells (HMC) were much less sensitive (IC50 2.77 ± 1.57 M vs 28.79 ± 15.86 M, 
respectively) (Fig. 2B). 
Reversal of the cerulenin effect by blockade of malonyl-CoA synthesis. FASN catalyzes 
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production of palmitic acid, an essential building block for long-chain fatty acids (28,31). By 
inhibiting FASN, cerulenin blocks the malonyl-CoA condensation step of fatty acid synthesis, 
causing a deficit in palmitic acid as well as an accumulation of malonyl-CoA (26,32-35). The 
toxicity of malonyl-CoA in cancer cells is thought to be mediated by inhibition of carnitine 
palmitoyltransferase 1-regulated fatty acid β-oxidation, in turn promoting the accumulation of the 
sphingolipid ceramide followed by the induction of the pro-apoptotic genes such as BNIP3, 
TRAIL and DAPK2, effectors in the ceramide-mediated apoptotic pathway (36).  
 
To evaluate the possibility that cerulenin effects in Nf2-/- cells might be related to reduced 
palmitic acid availability, we supplemented the growth media of Nf2-/- and Nf2f/f cells with 
palmitic acid. This addition did not reverse the toxicity of cerulenin (Fig. 3A). We next 
considered whether lack of fatty acid precursors or accumulation of malonyl-CoA might promote 
cell death in cerulenin-treated Nf2-/- cells. We therefore knocked down acetyl-CoA carboxylase 1 
(ACC1, encoded by Acaca), which catalyzes production of malonyl-CoA from acetyl-CoA to 
provide building blocks for FASN (Fig. 3B), together with cerulenin treatment. Knockdown of 
Acaca led to a striking reduction in cerulenin- and GSK2194069-induced toxicity (Fig. 3C and 
S2A-B). Conversely, we tested the effect and knockdown of malonyl-CoA decarboxylase (MCD, 
encoded by Mlycd) which catalyzes the conversion of malonyl-CoA back to acetyl-CoA (38). 
Mlycd knockdown increased the sensitivity of both cell lines to cerulenin and GSK2194069 (Fig. 
3D and S2C). Chemical inactivation of ACC1 by 5-(tetradecyloxy)-2-furoic acid (TOFA) had a 
similar effect as Acaca knockdown (Fig. 3E), consistent with the idea that elevated levels of 
malonyl-CoA are toxic to these cells, and suggesting that Nf2-/- cells produce more malonyl-CoA 
than Nf2f/f cells. Treatment with an ACC activator, 5-iodotubercidin, which blocks an AMP 
 16 
kinase mediated inhibitory phosphorylation of ACC1 (37), caused an increase in cerulenin 
toxicity in Nf2f/f cells, but had little effect on cerulenin toxicity in Nf2-/- cells (Fig. 3F). To 
determine if malonyl-CoA levels actually differ according to NF2 status, we performed UPLC-
MS/MS measurements of intracellular acetyl-CoA and malonyl-CoA in Nf2-/- and Nf2f/f cells (Fig. 
3G). These studies showed 50% higher level of acetyl-CoA in non-treated Nf2-/- cells compared 
to non-treated Nf2f/f cells (p=0.0497), and a significant increase of both acetyl-CoA (by 47%, 
p=0.0003) and malonyl-CoA (by 90%, p=0.0002) in cerulenin-treated Nf2-/- cells, but not in 
cerulenin-treated Nf2f/f cells. 
 
Upregulated lipogenesis in Nf2-deficient cells. Consistent with the metabolic profiling data that 
showed higher levels of fatty acids in Nf2-/- cells (Table 2), the selective toxicity of cerulenin 
appeared to be related to a greater accumulation of intermediate fatty acid synthesis products in 
Nf2-/- cells, and we hypothesized that the loss of Nf2 gene might cause a general increase in 
lipogenesis. We found markedly elevated levels of several key lipogenesis-related proteins in 
Nf2-/- relative to Nf2f/f cells, including ACC-1 (45%, p=0.003) and -2 (32%, p=0.002), FASN 
(60%, p=0.0007), SREBP1 (71%, p=0.0001), Lipin1 (63%, p=0.0001), ACL (52%, p=0.0137), 
and its phosphorylated active form (69%, p=0.0012), ACECS1 (59%, p=0.0022), and ACSL1 
(60%, p=0.0006). In addition, we found decreased Ser79 phosphorylation of ACC (59%, 
p=0.0032) in Nf2-/- MEFs, an indicator of high activity, as phosphorylation at this site inhibits 
ACC activity (39) (Fig. 4A and S3). Importantly, reintroduction of Merlin in SC4-9 cells 
decreased levels of these proteins and restored phosphorylation of ACC (Fig. 4B and S4). 
Consistent with the immunoblot data, quantitative PCR also showed significantly higher 
expression of lipogenesis-related genes in Nf2-/- MEFs relative to Nf2f/f MEFs (p < 0.001 for all 
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the genes studied) (Fig. 4C). The same trend was observed in SC4-9 cells compared to SC4-9-
merlin cells (Fig. 4C). Such an increase, especially of transcription factors SREBP1 and Lipin1, 
is consistent with our idea of upregulated lipid metabolism in Nf2-deficient cells. The modest 
effect of 5-iodotubercidin on Nf2-/- cells (Fig. 3F) is consistent with the low phosphorylation, and 
thus high activity, of ACC in these cells (Fig. 4A). Fig. 4D shows additional lipogenic enzyme 
roles in the fatty acid synthesis. Fasn and Acaca expression is controlled mainly by the 
transcription factor Sterol regulatory element binding protein 1 (SREBP1) (40,41), and Lipin1 is 
a major expression regulator of the rest of lipogenic enzymes (42,43). 
 
Torc1 signaling is essential for fatty acid synthesis regulation. It has been previously shown 
that Merlin inhibits MTOR (44). MTOR is a known metabolic sensor and has been shown to 
regulate SREBP1 (45) and Lipin1 (46). We hypothesized that activated MTOR in Nf2-deficient 
cells might cause the upregulation of fatty acid synthesis via upregulation of SREBP1 and 
Lipin1. We confirmed increased MTOR phosphorylation at serine 2448 in Nf2-deficient MEFs 
(Fig. 5A) and tried chemical and siRNA inactivation of MTOR in Nf2-null and WT MEFs. 
Chemical inactivation of MTOR either by the dual TORC1 and TORC2 inhibitor Torin1 or by 
the TORC1 inhibitor Everolimus led to a significant reduction of the cerulenin toxicity in Nf2-/- 
MEFs (1.5-fold difference in IC50 values, p = 0.027 and 0.0064 respectively), but had a non-
significant effect on WT MEFs (Fig. 5B). Immunoblot confirmed a drop in a triglyceride 
synthesis regulator Lipin1 and a FASN positive regulator SREBP1 protein levels caused by a 
decrease of MTOR phosphorylation at serine 2448 (Fig. 5B). The same effect was observed for 
RNAi knockdown of Mtor and TORC1 component Rptor, but not TORC2 component Rictor 
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(Fig. 5C and S5A-B). Thus, a key event causing fatty acid synthesis upregulation in Nf2-
deficient cells is TORC1 activation in the absence of Merlin. 
 
Discussion 
In this study, we show that cerulenin, an inhibitor of fatty acid synthesis is selectively toxic in 
cell lines lacking Merlin expression. Cerulenin has activity as an anti-obesity agent (21,47), but 
has also shown in vitro efficacy against the proliferation of colon (22), breast (48) and prostate 
cancer cells (21). Such sensitivity of certain cancer cells to this drug may be due to higher fatty 
acid synthesis levels compared to normal cells (24-26). Our findings showed that, despite their 
benign nature, Merlin-null cells have markedly elevated levels of fatty acid synthesis. Such cells 
displayed significantly higher levels of FASN and also ACC1 and 2, the enzymes that catalyze 
production of malonyl-CoA from acetyl-CoA. Moreover, Nf2-deficient cells had low levels of 
ACC phosphorylation, indicating high activity of this enzyme (39). The higher level of ACC 
expression is consistent with the pronounced rescue effect of TOFA, an ACC inhibitor, on 
cerulenin-treated Nf2-/- MEFs (Fig. 4E). FASN inhibitors have previously been shown to reduce 
proliferation of human malignant mesothelioma cells (49), which are often characterized by loss 
of function mutations in CDKN2A/p14(ARF) and NF2. Gabrielson et al. reported that Fasn is 
overexpressed in 22 of 30 human mesothelioma tissue samples compared with normal tissues, 
including mesothelium (49). They found that the growth of orthotopic xenografts of malignant 
mesothelioma cells was strongly inhibited in mice treated with the Fasn inhibitor C75. In 
addition, Haase et al. reported that Fasn expression was elevated in 70% of atypical grade II and 
anaplastic grade III meningiomas, and that treatment with cerulenin significantly decreased NF2-
null meningioma cell survival in vitro and reduced tumor volumes in xenografts (50). These 
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results, combined with our data in Nf2-null MEFs and Schwann cells, suggest that changes in 
lipid synthesis may be a general function in cells lacking Merlin.  
Inhibitors such as cerulenin have also shown to have efficacy in a number of non-NF2 related 
cancer cell types in vitro and in preclinical models (24). In some cases, it has been proposed that 
these effects are mediated by targets other than FASN. For example, cerulenin induces apoptosis 
in melan-a cells, but these effects appear to be independent of Fasn inhibition, and are instead 
thought to be mediated by an oxidative stress-associated mechanism that ultimately results in 
mitochondrial dysfunction (51). FASN inhibitors have also been shown to affect the activity 
level of the HER2/PI3K/AKT signaling pathway in U2OS cells (52). However, in our studies in 
the setting of Merlin deficiency, similar cellular and metabolic effects were seen with other three 
distinct small molecule FASN inhibitors as well as with Fasn siRNA. Thus, we believe that the 
effects of cerulenin on Merlin-null cells are related to FASN inhibition, with subsequent build-up 
of toxic intermediates such as malonyl-CoA, as opposed to off-target effects. This supposition is 
supported by the loss of cerulenin toxicity in Merlin-null cells when an ACC inhibitor is also 
added to the cells (Fig. 3E). 
As a clinical agent, cerulenin suffers from relatively poor bioavailability. In addition, this 
compound, as well as the synthetic analog C75, has undesirable side effects that include anorexia 
and weight loss, most likely due to effects on production of neuropeptide Y in the hypothalamus 
as well as activation of mitochondrial fatty acid oxidation (24,47,53). In our experiments, mice 
tolerated treatment well, and did not experience weight loss. Still, a decrease in the FASN levels 
of cerulenin-treated tumours indicates that the drug reached its target in the in vivo studies. 
Unfortunately, the quality of antibodies against lipogenic enzymes did not allow to confirm their 
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downregulation in the xenograft experiments, and the size of the treated tumours was too small 
for the HPLC analysis. It is possible that combining Fasn inhibitors with inhibitors of malonyl-
CoA decarboxylase or inhibitors of AMP kinase (resulting in ACC activation and accumulation 
of malonyl CoA), would show additive or synergistic effects in vivo. We showed that activation 
of MTOR at Ser 2448 in Nf2-null cells is a key element in lipogenesis upregulation in such cells 
(Fig. 5A-C). As FASN expression is regulated by the transcription factor sterol regulatory 
element-binding protein 1c (SREBP1c) via the ERK and PI3K/AKT/MTOR pathways (54,55), 
modulators of these signaling pathways might also be reasonable candidates to combine with 
FASN inhibitors. 
 
While our findings suggest that upregulated fatty acid synthesis is a key element in cerulenin 
selectivity against Nf2-deficient cell lines, we also found other metabolic changes that might be 
useful in designing targeted therapies. For example, we found a significant increase in 
mitochondrial respiration rate and a drop in glycolysis metabolites in both FH912 (Nf2-/-) 
Schwann cells and Nf2-/- MEFs (Table 1 and Fig. S6). Thus, Nf2-deficient tumor cells differ in 
their utilization of glucose compared to typical malignant cancer cells, which are often 
characterized by aerobic glycolysis. Interestingly, Nf2-/- and control MEFs react differently to 
cerulenin treatment (Table S3). While cerulenin causes an increase in TCA metabolite level in 
normal cells, Nf2-deficient cells retain the same level of TCA metabolites. We speculate that 
normal cells compensate a decrease of energy production from fatty acid oxidation in the 
presence of cerulenin by upregulating Krebs’ cycle. As Nf2-/- MEFs do not demonstrate such 
compensation it suggests there might be an initial fatty acid oxidation impairment in these cells. 
This supposition is also indirectly confirmed by the decrease in fatty acid oxidation gene 
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expression in Nf2-deficient cells (Fig. S7). Additionally, we noted a profound drop in amino acid 
levels, especially in glutamate metabolites, dipeptide, and polypeptide levels in Nf2-null cells 
(Table S2). Such a general decrease in amino acid and peptide levels might indicate an increased 
demand of building blocks for protein synthesis, which is likely related to the increased growth 
rate of Nf2-deficient cells. Similarly, a drop in glutamine level might be evidence of increased 
glutaminolysis supporting an increased energy demand. It is also of potential interest that Nf2-
deficient cells showed an increased level of coenzymes (Table S1). This change specifically 
affected pantothenate and phosphopantetheine levels, and NAD+ and NADH levels. Pantothenate 
and phosphopantetheine are essential for coenzyme A synthesis, and elevation of their levels is 
an indication of higher lipid, carbohydrate, and amino acid metabolism rates (56). Such an 
increase in NAD+ and NADH levels is likely necessary to support greater energy metabolism in 
Nf2-deficient cells.  
 
In summary, we have shown for the first time that Nf2-deficiency is associated with a profound 
reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic 
processes, and that this altered metabolism might be exploited therapeutically. In particular, the 
increased dependence of Nf2-deficient cells on lipid synthesis suggests that Fasn inhibitors, alone 
or in combination with other agents that increase malonyl-CoA levels, might be useful in treating 
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citrate 1.47 0.45 
succinate 2.62 1.56 
fumarate 1.23 0.47 
malate 1.94 0.33 
Oxidative 
Phosphorylation 
acetylphosphate 1.8 0.45 
pyrophosphate 0.81 0.78 





glucose 0.32 1.45 
glucose-6-phosphate 0.74 0.05 
glucose 1-phosphate 1.12 0.68 
fructose-6-phosphate 0.82 0.16 
3-phosphoglycerate 0.12 0.52 
pyruvate 0.56 1.59 
lactate 1.13 1.1 
glycerate 0.35 0.89 
Table 1. Tricarbonic acid cycle and glycolysis metabolite level alteration in Nf2-deficient 
cells. Levels of metabolites as measured by gas chromatography and high performance liquid 
chromatography. Bolded, underlined numbers indicate significant differences (p ≤ 0.05) between 
the groups shown, metabolite ratio of <1.00. Greyed, underlined boxes indicate significant 
difference (p ≤ 0.05) between the groups shown; metabolite ratio of ≥ 1.00. Two-tailed Welch’s 
t-test was used to compare FH912 and FC912 cells, n = 5. Two-way ANOVA contrasts were 
used to compare Nf2-/- and Nf2f/f MEFs and to evaluate cerulenin treatment effects. 
 28 



















stearate (18:0) 1.17 1.33 




arachidate (20:0) 1.41 1.82 
eicosenoate (20:1n9 or 
11) 
0.93 2.78 
erucate (22:1n9) 0.92 2.67 
nervonate (24:1n9) 0.87 2.88 

















  linoleate (18:2n6) 0.95 2.21 
  


















15-methylpalmitate  1.41 1.08 
17-methylstearate 1.28 2.1 
Table 2. Upregulation of Fatty Acid Synthesis in Nf2-deficient cells. Samples were processed 




Figure 1. Effects of FASN inhibition. A) Cerulenin dose response curve in Nf2-/- and Nf2f/f 
MEFs, SC4-9 and RT4 cells. Cells were treated with the indicated amounts of cerulenin for 48 
hr. Experiments were done in quadruplicates and repeated 4 times. Alamar Blue was used for 
read-outs. Mean values and 95% confidence intervals are shown on graphs. B) Increased Casp3 
cleavage in Nf2-/- MEFs transfected with anti-Fasn siRNA. Cells were transfected by 
electroporation with anti-Fasn and scrambled (negative control) siRNAs, final concentration 100 
nM, and plated into 6-well plates (250,000 cells/well). C) Effect of reintroducing Merlin in Nf2-
deficient schwannoma cells. SC4-9 mouse schwannoma cells, transiently transfected with empty 
pBabe-puro plasmid or pBabe-Merlin plasmid, were tested for sensitivity to cerulenin. All 
experiments were done in quadruplicates and repeated 4 times. Alamar Blue was used for read-
outs. Mean values and 95% confidence intervals are shown on graphs.  At 24 h post-transfection, 
lysates were analyzed by immunoblotting using rabbit anti-FASN and anti-cleaved Casp3 
antibodies. Typical blots are shown. Band intensities were quantified using ImageJ software and 
normalized to GAPDH band intensities. All experiments were repeated 3 times. Mean values and 
95% confidence intervals are shown on graphs. **** – p ≤ 0.0001. D-F) Effects of FASN 
inhibitors GSK2194069, C75, and Luteolin. Experiments were done using the indicated cell 
types in quadruplicate and repeated 4 times. Alamar Blue was used for read-outs. Mean values 
and 95% confidence intervals are shown on graphs. G) In vivo effects of cerulenin. 3x106 SC4-9 
cells in matrigel:PBS 1:1 per mouse (female nu/nu) were injected subcutaneously. 30 mg/kg/day 
of cerulenin or 3 mg/kg/day of GSK2194069 in corn oil were given by oral gavage daily starting 
day 3 after injection; n = 6. Mean values and 95% confidence intervals are shown on graphs. 
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Figure 2. Effects of FASN inhibitors in human schwannoma and meningioma cells. A) Dose 
response to FASN inhibitors in primary human schwannoma cells (NF2-/-) compared to normal 
Schwann cells (NF2+/+). Cells were incubated with indicated concentrations of GSK2194069 for 
72 hours.  Proliferation (Ki67, first panel), apoptosis (cleaved Casp3, second panel) and merlin 
status (third panel), were confirmed by immunocytochemistry and confocal microscopy using 
DAPI for the total cell count and phalloidin for cytoskeleton staining. Quantification of 
proliferation and apoptosis was performed using ZEN software. B) Dose response in primary 
human meningioma cells (NF2-/-) to GSK2194069 compared to normal meningeal cells (NF2+/+). 
Cells were incubated with indicated concentrations of GSK2194069 for 72 hours, proliferation 
(Ki67, first panel) and apoptosis (cleaved Casp3, second panel) were confirmed by 
immunocytochemistry using DAPI for the total cell count, merlin status was confirmed by 
immunoblotting third panel). Experiments were performed in at least triplicates using at least 
three independent batches of cells from different individuals. # - 0.05 < p < 0.07, * - p < 0.05; ** 
- p < 0.01. Mean ± s.e.m. is shown on graph.  
 
Figure 3. Modulation of the effect of cerulenin by genetic and chemical modulation of 
acetyl-CoA carboxylase (ACC1) and malonyl-CoA decarboxylase (MCD) activity. A) 
Supplementing culture media with palmitate does not reverse the effect of cerulenin. Palmitate 
sodium salt (5 μM) was added together with the indicated concentrations of cerulenin, 4 hours 
after cell seeding, and cells were then incubated for 48 hours. An experiment was done in 
quadruplicate and repeated 4 times. Mean values and 95% confidence intervals are shown on 
graphs. B) Cartoon of Palmitate synthetic pathway. Sites of action of small molecule inhibitors 
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are indicated. ACC = acetyl-CoA carboxylase, MCD = malonyl-CoA decarboxylase, ACP = acyl 
carrier protein, FASN = fatty acid synthase, TOFA = tetradecyloxyfuroic acid. C) Effect of 
Acaca knockdown on FASN inhibition. Cells were transfected by electroporation with anti-
Acaca and scrambled (negative control) siRNAs. The indicated amounts of cerulenin were added 
in 24 hours and incubated for 48 hours. Parallel transfections for knockdown control were done 
in a 6-well format. Experiments were done in quadruplicates and repeated 3 times. Mean values 
and 95% confidence intervals are shown on graphs. D) Effect of Mlycd knockdown on FASN 
inhibition. Cells were transfected by electroporation with anti-Mlycd and scrambled (negative 
control) siRNAs. Indicated amounts of cerulenin were added in 24 hours and incubated for 48 
hours. Parallel transfections for knockdown control were done in a 6-well format. Experiments 
were done in quadruplicates and repeated 4 times. Mean values and 95% confidence intervals are 
shown on graphs. E) Effect of chemical inhibition of ACC on cerulenin toxicity. The ACC 
inhibitor TOFA (25 μM) was added together with the indicated concentrations of cerulenin, 4 
hours after cell seeding, and cells were then incubated for 48 hours. F) Effect of chemical 
activation of ACC on cerulenin toxicity. The ACC activator 5-iodotubericidin (2.5 μM) was 
added together with the indicated concentrations of cerulenin, 4 hours after cell seeding, and 
cells were then incubated for 48 hours. All experiments were done in quadruplicates and 
repeated 3 times. Mean values and 95% confidence intervals are shown on graphs. G) Effects of 
Merlin on acyl-CoA levels. UPLC-MS/MS measurements of acetyl-CoA and malonyl-CoA. 
MEFs were treated with 0.1 μL/mL DMSO or 5 μM cerulenin for 24 hours. Experiments were 
repeated 3 times. Mean values and 95% confidence intervals are shown on graphs. * – p ≤ 0.05, 
*** – p ≤ 0.001.  
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Figure 4. Effects of Merlin on lipogenesis-related gene expression. A) Immunoblot detection 
of levels of expression and phosphorylation of lipogenesis-related proteins in Nf2-/- and Nf2f/f 
MEFs. B) Immunoblot detection of levels of expression and phosphorylation of lipogenesis-
related proteins in SC4-9 Babe (SC4-9 cells transiently transfected with empty pBabe-puro 
plasmid); SC4-9 Merlin (SC4-9 cells transiently transfected with pBabe-Merlin plasmid). 
Typical blots are shown. C) Lipogenesis gene expression quantification by qPCR. RNA 
quantification was performed on Nf2-/- and Nf2f/f MEFs; SC4-9 Babe (SC4-9 cells transiently 
transfected with empty pBabe-puro plasmid); SC4-9 Merlin (SC4-9 cells transiently transfected 
with pBabe-Merlin plasmid); and Nf2-/- (FH912) and Nf2f/f (FC912) mouse Schwann cells. All 
experiments were repeated 4 times Mean and 95% CI are shown on graphs. *** – p ≤ 0.001. D) 
Enzymes involved in fatty acid sythesis. ACC1, Acaca = Acetyl-CoA carboxylase 1; ACC2, 
Acacb = Acetyl-CoA carboxylase 2; ACL = ATP citrate lyase; SREBP1 = Sterol regulatory 
element binding protein 1. ACECS1, Acss2 = Acetyl-CoA synthase 1; ACSL1 = Acyl-CoA 
synthetase long-chain family member 1. Cpt1c = Carnitine palmitoyl transferase Ic. Cpt2 = 
Carnitine palmitoyl transferase II. Mlycd = Malonyl-CoA decarboxylase. 
 
Figure 5. Role of TORC1 in lipogenesis upregulation in Nf2-/- MEFs. A) Immunoblot 
detection of MTOR activation in Nf2-/- vs Nf2f/f MEFs. B) Effect of chemical inhibition of MTOR 
on cerulenin toxicity. The TORC1 and TORC2 inhibitor Torin1 (25 nM) or TORC1 inhibitor 
Everolimus (100 nM) were added together with the indicated concentrations of cerulenin, 4 
hours after cell seeding, and cells were then incubated for 48 hours. C) Mtor, Rptor and Rictor 
siRNA transfections. Cells were transfected by electroporation with anti-Mtor, Rptor or Rictor 
and scrambled (negative control) siRNAs. The indicated amounts of cerulenin were added in 24 
 33 
hours and incubated for 48 hours. All experiments were repeated 2 times, dose response curves 
were done in quadruplicates, and for WBs each lysate type was run in duplicates for transfer 
consistency control. Mean values and 95% confidence intervals are shown on graphs. 
